Related Experiment Video
Updated: Aug 17, 2026

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
Have all the ICD primary prevention trials excluded an important group of patients?
1The Cardiac Arrhythmia Service, Lahey Medical Center, Burlington, Massachusetts 01805, USA.
Insights
Implantable cardioverter defibrillator (ICD) therapy may benefit patients with ventricular dysfunction after revascularization. Early ICD use in selected patients with perioperative ventricular arrhythmia is suggested pending further trials.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Devices
Background:
- Primary prevention trials for implantable cardioverter defibrillator (ICD) therapy typically exclude patients early post-revascularization.
- Clinicians frequently encounter patients with ventricular dysfunction and nonsustained ventricular tachyarrhythmia shortly after revascularization.
- Current management lacks evidence-based guidelines, relying on clinician discretion.
Discussion:
- Emerging evidence suggests this patient population faces an elevated risk of life-threatening ventricular tachyarrhythmia.
- The study proposes considering ICD therapy for carefully selected patients experiencing perioperative ventricular arrhythmia.
- This recommendation is made pending the results of prospective clinical trials.
Key Insights:
- Patients with ventricular dysfunction post-revascularization are at high risk for serious arrhythmias.
- Implantable cardioverter defibrillators (ICDs) are a potential therapeutic option for this group.
- Evidence-based guidelines are needed for managing these complex cardiac patients.
Outlook:
- Prospective trials are crucial to establish definitive guidelines for ICD use in this population.
- Further research will clarify the long-term efficacy and safety of ICDs in early post-revascularization patients.
- Optimizing patient selection for ICD therapy remains a key focus for future studies.
Abstract:
Primary prevention trials of implantable cardioverter defibrillator (ICD) therapy have generally excluded patients early after revascularization. Clinicians are commonly faced with patients who have ventricular dysfunction and nonsustained ventricular tachyarrhythmia developing shortly after revascularization. Since there are no evidence-based guidelines, management is currently at the discretion of the treating clinician. Recently, evidence has emerged that this patient population is at increased risk of development of life-threatening ventricular tachyarrhythmia and, pending prospective trials, we suggest that ICD therapy should be used in appropriately selected patients with perioperative ventricular arrhythmia.
Related Concept Videos
Preventive Healthcare Services
Clinical Trials: Overview
Blinding
Levels of Health Promotion and Illness Prevention
In primary prevention, actions taken before disease onset prevent the disease from...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...